The results suggested that the expression of REV1 was significantly elevated relative to normal controls in cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck cancer (HNSC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC) and stomach adenocarcinoma (STAD). The gene discussed is REV1; the disease is head and neck cancer.